ClinicalTrials.gg
Enrolling by invitationNCT07078370VCAB-2Updated Jul 29, 2026

Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass

An interventional study of ATEV with ESS in Coronary Artery Disease and Multi Vessel Coronary Artery Disease, sponsored by Vascudyne, Inc.. Enrolling by invitation at 4 sites in Poland. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Vascudyne, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.

Planned enrollment
109th of 114
20 · median 348
Started
2025
with 10 others
No phase
64 of 154
17 open now
Primary completion
2027-03
later than 24 of 46 live
Registered
144th of 154
by date

Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 109th largest by planned enrollment of the 114 interventional ones that give a count, is one of 11 that started in 2025, is one of 64 with no phase, reaches primary completion later than 24 of the 46 other live ones, and was the 144th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Coronary Artery Disease with a site in Poland, or all of them as a file.
02

Study summary

To assess safety and feasibility of a coronary bypass created with Vascudyne Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) in patients requiring multi vessel coronary artery bypass grafting (CABG).

Read the detailed description

Prospective, non-randomized, evaluation clinical study to assess the feasibility of Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) for secondary coronary targets in patients needing multiple coronary artery bypass.

Patients will be implanted with a single ATEV with ESS bypass (single proximal and distal anastomoses) to the second or third coronary arteries (CA) bypass target.

The primary target CA shall be bypassed using an arterial graft. The left anterior descending (LAD) CA bypass, if needed, shall be bypassed using the left internal mammary artery (LIMA). A native vessel shall be used for any additional targets as needed.

03

Conditions studied

  • Coronary Artery Disease
  • Multi Vessel Coronary Artery Disease

Keywords

  • CABG
  • ATEV
  • Tissue Engineered Vessel
  • coronary artery disease
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the following inclusion criteria:

  1. Patient with limited quantity of good quality saphenous vein graft (SVG) for planned operation per the surgeon discretion.
  2. Bypass to at least two coronary arteries (CA); primary target shall be an Internal mammary artery (IMA) bypass to the Left anterior descending (LAD) artery, and one IMD to a secondary target CA that:

    • requires ≤ 15cm long conduit
    • has a diameter at least 1.5 mm at targeted landing site
    • has at least 70% stenosis proximal to the target bypass
    • evidence that sufficient runoff will exist in the target vessel after bypass
  3. Male or female patients between the ages of 45 and 75 years inclusive.
  4. Elective patient, selected and accepted by the local Heart Team and confirmed by the Sponsor's Screening Committee for an on-pump full sternotomy coronary artery bypass grafting (CABG) surgery.
  5. Female subjects must be of non-, which is defined as (at least 1 year without menses prior to Screening) or documented surgically sterile or post hysterectomy (at least 1 month prior to Screening).
  6. Patient has been informed of the nature of the study, agrees to its provisions, and has provided written .
  7. Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up cardiac ultrasound and coronary angiogram or computed tomography (CT).
  8. Patient is willing to be compliant with prescribed anticoagulant therapy (critical to preventing thrombus in the ATEV).

Exclusion criteria

Exclusion Criteria:

  1. Patients with \< 35%.
  2. Patients with diffusely diseased coronary arteries suggestive of either poor target quality, or poor vessel runoff.
  3. Patients requiring emergency surgery.
  4. Patients with cardiogenic shock.
  5. Patients with any prior open cardiac surgery such as CABG.
  6. Any planned concomitant cardiac surgery, including but not limited to: valve surgery, repair of intracardiac shunt, surgical arrhythmia ablation.
  7. History of cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation.
  8. Myocardial infarction (MI) within 21 days or cerebral vascular accident (CVA) within 90 days of the CABG procedure.
  9. Concomitant life-threatening disease likely to limit to less than 2 years.
  10. Patient with uncontrolled diabetes ( > 8%).
  11. Chronic Kidney Disease (CKD) with (GFR) \<45 mL/min/1.73m2 (Category: G3b-G5 according to Kidney Disease: Improving Global Outcomes (KDIGO)).
  12. Moderate to severe (COPD) with a forced expiratory volume (FEV) \<1.5 L/sec or 45% predicted .
  13. Patient with known interstitial lung disease, diagnosed by imaging or pulmonary function tests, including Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO).
  14. Endocarditis, pericarditis, or any other active systemic infection that would interfere with patient safety.
  15. Patient on preoperative anticoagulant, or pre existing indication for anticoagulation (e.g. atrial fibrillation, history of thromboembolism), or with known coagulation disorder.
  16. Abnormal blood values (e.g. leukopenia, anemia, thrombocytopenia, or thrombocytosis with Count >400,000 per mL that could influence graft hemostasis or patient recovery
  17. Known allergies to study device components: Nitinol, Nickel, Titanium, or agents/medication such as contrast agents, antiplatelet therapy, beta-blocker, or statins required for study assessment or optimal post-CABG medical treatment (hospital standard of care).
  18. to or known serious allergy to anticoagulant, aspirin, or planned antiplatelet (clopidogrel, ticagrelor, prasugrel) and factor Xa inhibitor therapy.
  19. Any planned medical intervention or condition within the 12 months following ATEV implantation that requires temporary or permanent discontinuation of antiplatelet or anticoagulant therapy.
  20. History of heparin-induced thrombocytopenia.
  21. Documented or suspected untreated diffuse peripheral vascular disease such as: carotid stenosis or claudication of the extremities.
  22. Immunodeficiency including (HIV), active disease, or on therapy.
  23. Treatment with any drug or device within 60 days prior to study entry or ongoing participation in another clinical study of an investigational product.
  24. Subject has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance.
  25. Has any other condition, in the opinion of the principal investigator, which would put the patient at increased risk from participating in the study or otherwise prevent participation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ATEV with ESS

    Surgical implant of Acellular Tissue Engineered Vessel with External Support Structure as Coronary Artery bypass

    Device: ATEV with ESS

Interventions

  • DeviceATEV with ESS

    Patients will be implanted with a single Acellular Tissue Engineered Vessel with External Support Structure bypass (single proximal and distal anastomoses) to the second or third coronary artery bypass target

    Also known as: CABG

06

What researchers measure

Primary outcomes

  1. Successful implantation

    Successful implantation as defined by meeting each of the following points: 1. Completion of both a proximal and distal anastomosis, 2. Placement of ESS, 3. No evidence of ATEV twist or kink on direct visual inspection.

    Time frame: 30 days.

  2. Freedom from Major Adverse Cardiac and Cerebrovascular events (MACCE) at 30 days.

    Freedom from Major Adverse Cardiac and Cerebrovascular events (MACCE) at 30 days. MACCE is defined as combination of: 1. death, 2. non-fatal stroke, 3. non-fatal myocardial infarction, 4. unplanned revascularization 5. hospitalization due to heart failure

    Time frame: 30 days.

Secondary outcomes

  1. Patency at 1 and 6 months

    Patency of conduit assessed by Coronary Computed Tomography Angiography (CCTA) results at 1 and 6 months post-implantation.

    Time frame: 1 month and 6 months.

  2. Patency at 12 months

    Patency of conduit assessed by angiography results at 12 months, defined according to Fitzgibbon classification.

    Time frame: 12 months.

  3. Lumen Diameter Uniformity

    Lumen Diameter Uniformity of all bypasses assessed by angiography results at 12 months.

    Time frame: 12 months.

  4. Immune Response

    Panel Reactive Antibody assessment via serum assay at baseline, 1, 6, and 12 months.

    Time frame: 12 months.

  5. Device Serious Adverse Event (SAE)

    Device Related Serious Adverse Events identified at 6, 12, 24, 48 and 60 months follow-ups.

    Time frame: 6 months, 12 months, 24 months, 48 months, and 60 months.

  6. Freedom from (major adverse cardiac and cerebrovascular events) MACCE

    Freedom from (major adverse cardiac and cerebrovascular events) MACCE at 6, 12, 24, 48 and 60 months follow-ups.

    Time frame: 6 months, 12 months, 24 months, 48 months, and 60 months.

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 19 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 22, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07078370
Lead sponsor
Vascudyne, Inc.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Aug 28, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Krzysztof Wrobel, MD PhD
principal investigator · MEDICOVER SP Z O.O.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion